MET exon 14 and MET-amplified non-small-cell lung cancer

What changed: MET exon 14 and MET-amplified non-small-cell lung cancer

Every dated change on the records linked to MET exon 14 and MET-amplified non-small-cell lung cancer, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.

Regulatory1Trial result2Milestone5This record1

FollowWatch this cancer and Saved shows what changed since you last looked.Follow by feed

September 2026 · 1

2026-09-17This recordMET exon 14 and MET-amplified non-small-cell lung cancer
Facts on this page last checked
When this page itself was last checked or edited.

2025 · 1

2025MilestoneTelisotuzumab vedotin
Telisotuzumab vedotin approved; SACHI: osimertinib plus savolitinib for MET-amplified resistance
A milestone in how this cancer is treated.

2024 · 2

January 2022 · 1

2022-01RegulatoryTelisotuzumab vedotin
Telisotuzumab vedotin: designation granted (US)
Breakthrough Therapy designation, c-MET overexpressing NSCLC

2021 · 1

2021MilestoneTepotinib
Tepotinib approved; savolitinib approved in China
A milestone in how this cancer is treated.

2020 · 2

2015 · 1

2015MilestoneMET
MET exon 14 skipping shown to be a targetable driver with crizotinib responses
A milestone in how this cancer is treated.